InvestorsHub Logo
Followers 335
Posts 19015
Boards Moderated 0
Alias Born 08/25/2007

Re: None

Thursday, 09/22/2016 11:22:14 PM

Thursday, September 22, 2016 11:22:14 PM

Post# of 2028
Allergan buys another NASH therapy developer for $50M plus milestones
Akarna develops small molecule drugs for the treatment of inflammatory and fibrotic diseases. Its lead product candidate is AKN-083, a preclinical-stage FXR agonist in development for the treatment of NASH

DONT LISTEN TO ME IM CANADIANNNNNNNN

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CANF News